230 related articles for article (PubMed ID: 33327623)
1. Genetic and Acquired Heterotopic Ossification: A Translational Tale of Mice and Men.
Cappato S; Gamberale R; Bocciardi R; Brunelli S
Biomedicines; 2020 Dec; 8(12):. PubMed ID: 33327623
[TBL] [Abstract][Full Text] [Related]
2. Heterotopic Ossification in Mouse Models of Fibrodysplasia Ossificans Progressiva.
Chakkalakal SA; Shore EM
Methods Mol Biol; 2019; 1891():247-255. PubMed ID: 30414138
[TBL] [Abstract][Full Text] [Related]
3. Depletion of Mast Cells and Macrophages Impairs Heterotopic Ossification in an Acvr1
Convente MR; Chakkalakal SA; Yang E; Caron RJ; Zhang D; Kambayashi T; Kaplan FS; Shore EM
J Bone Miner Res; 2018 Feb; 33(2):269-282. PubMed ID: 28986986
[TBL] [Abstract][Full Text] [Related]
4. Palovarotene Inhibits Heterotopic Ossification and Maintains Limb Mobility and Growth in Mice With the Human ACVR1(R206H) Fibrodysplasia Ossificans Progressiva (FOP) Mutation.
Chakkalakal SA; Uchibe K; Convente MR; Zhang D; Economides AN; Kaplan FS; Pacifici M; Iwamoto M; Shore EM
J Bone Miner Res; 2016 Sep; 31(9):1666-75. PubMed ID: 26896819
[TBL] [Abstract][Full Text] [Related]
5. Progressive osseous heteroplasia.
Kaplan FS; Shore EM
J Bone Miner Res; 2000 Nov; 15(11):2084-94. PubMed ID: 11092391
[TBL] [Abstract][Full Text] [Related]
6. The role of Activin A in fibrodysplasia ossificans progressiva: a prominent mediator.
Lin H; Shi F; Gao J; Hua P
Biosci Rep; 2019 Aug; 39(8):. PubMed ID: 31341010
[TBL] [Abstract][Full Text] [Related]
7. Role of osteoclasts in heterotopic ossification enhanced by fibrodysplasia ossificans progressiva-related activin-like kinase 2 mutation in mice.
Kawao N; Yano M; Tamura Y; Okumoto K; Okada K; Kaji H
J Bone Miner Metab; 2016 Sep; 34(5):517-25. PubMed ID: 26204847
[TBL] [Abstract][Full Text] [Related]
8. The Expansion of Heterotopic Bone in Fibrodysplasia Ossificans Progressiva Is Activin A-Dependent.
Upadhyay J; Xie L; Huang L; Das N; Stewart RC; Lyon MC; Palmer K; Rajamani S; Graul C; Lobo M; Wellman TJ; Soares EJ; Silva MD; Hesterman J; Wang L; Wen X; Qian X; Nannuru K; Idone V; Murphy AJ; Economides AN; Hatsell SJ
J Bone Miner Res; 2017 Dec; 32(12):2489-2499. PubMed ID: 28782882
[TBL] [Abstract][Full Text] [Related]
9. Neofunction of ACVR1 in fibrodysplasia ossificans progressiva.
Hino K; Ikeya M; Horigome K; Matsumoto Y; Ebise H; Nishio M; Sekiguchi K; Shibata M; Nagata S; Matsuda S; Toguchida J
Proc Natl Acad Sci U S A; 2015 Dec; 112(50):15438-43. PubMed ID: 26621707
[TBL] [Abstract][Full Text] [Related]
10. An mTOR Signaling Modulator Suppressed Heterotopic Ossification of Fibrodysplasia Ossificans Progressiva.
Hino K; Zhao C; Horigome K; Nishio M; Okanishi Y; Nagata S; Komura S; Yamada Y; Toguchida J; Ohta A; Ikeya M
Stem Cell Reports; 2018 Nov; 11(5):1106-1119. PubMed ID: 30392977
[TBL] [Abstract][Full Text] [Related]
11. Stem cells and heterotopic ossification: Lessons from animal models.
Lees-Shepard JB; Goldhamer DJ
Bone; 2018 Apr; 109():178-186. PubMed ID: 29409971
[TBL] [Abstract][Full Text] [Related]
12. Hematopoietic stem-cell contribution to ectopic skeletogenesis.
Kaplan FS; Glaser DL; Shore EM; Pignolo RJ; Xu M; Zhang Y; Senitzer D; Forman SJ; Emerson SG
J Bone Joint Surg Am; 2007 Feb; 89(2):347-57. PubMed ID: 17272450
[TBL] [Abstract][Full Text] [Related]
13. Hints on transcriptional control of essential players in heterotopic ossification of Fibrodysplasia Ossificans Progressiva.
Ravazzolo R; Cappato S; Bocciardi R
Bone; 2018 Apr; 109():187-191. PubMed ID: 29100956
[TBL] [Abstract][Full Text] [Related]
14. ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblast differentiation and bone formation.
van Dinther M; Visser N; de Gorter DJ; Doorn J; Goumans MJ; de Boer J; ten Dijke P
J Bone Miner Res; 2010 Jun; 25(6):1208-15. PubMed ID: 19929436
[TBL] [Abstract][Full Text] [Related]
15. Fibrodysplasia Ossificans Progressiva (FOP): A Segmental Progeroid Syndrome.
Pignolo RJ; Wang H; Kaplan FS
Front Endocrinol (Lausanne); 2019; 10():908. PubMed ID: 31998237
[TBL] [Abstract][Full Text] [Related]
16. Development of New Therapeutic Agents for Fibrodysplasia Ossificans Progressiva.
Luo Y; Alsamarah A; Zhang K; Hao J
Curr Mol Med; 2016; 16(1):4-11. PubMed ID: 26695699
[TBL] [Abstract][Full Text] [Related]
17. ACVR1
Haupt J; Stanley A; McLeod CM; Cosgrove BD; Culbert AL; Wang L; Mourkioti F; Mauck RL; Shore EM
Mol Biol Cell; 2019 Jan; 30(1):17-29. PubMed ID: 30379592
[TBL] [Abstract][Full Text] [Related]
18. NF-κB/MAPK activation underlies ACVR1-mediated inflammation in human heterotopic ossification.
Barruet E; Morales BM; Cain CJ; Ton AN; Wentworth KL; Chan TV; Moody TA; Haks MC; Ottenhoff TH; Hellman J; Nakamura MC; Hsiao EC
JCI Insight; 2018 Nov; 3(22):. PubMed ID: 30429363
[TBL] [Abstract][Full Text] [Related]
19. Morpholino-Mediated Exon Skipping Targeting Human ACVR1/ALK2 for Fibrodysplasia Ossificans Progressiva.
Maruyama R; Yokota T
Methods Mol Biol; 2018; 1828():497-502. PubMed ID: 30171563
[TBL] [Abstract][Full Text] [Related]
20. Multi-system involvement in a severe variant of fibrodysplasia ossificans progressiva (ACVR1 c.772G>A; R258G): A report of two patients.
Kaplan FS; Kobori JA; Orellana C; Calvo I; Rosello M; Martinez F; Lopez B; Xu M; Pignolo RJ; Shore EM; Groppe JC
Am J Med Genet A; 2015 Oct; 167A(10):2265-71. PubMed ID: 26097044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
